In the case of standard oral glutathione, the bioavailability is notoriously low
mild redness or soreness at the site can occur, and rotating sites helps
From a pharmacological safety perspective, the adverse effect profile of retatrutide based on Phase 1 and Phase 2 clinical trial data (including the NEJM 2023 Phase 2 trial) includes: Gastrointestinal effects: Nausea, vomiting, diarrhoea, and constipation (the most commonly reported side effects in trial participants) Injection site reactions: Redness, swelling, or discomfort at the injection site Cardiovascular effects: Increases in heart rate have been observed in trial participants [21] [22] Hypoglycaemia: Particularly relevant in individuals with diabetes or those taking insulin, sulfonylureas, or other glucose-lowering agents Potential thyroid effects: GLP-1 receptor agonists have been associated with thyroid C-cell changes in rodent studies
93,94,95,96 Dysfunctional lysosomes and genetic variants such as IRGM further exacerbate disease progression
248 These mutations are more prone to ubiquitination, leading to an imbalanced TGF- pathway and thus to tumorigenesis